A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors

PURPOSE: Enzastaurin, an oral serine/threonine kinase inhibitor, targets the protein kinase C and AKT pathways with anti-tumor and anti-angiogenic effects. Erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has activity in solid tumors. Based on the promising combination of EGFR i...

Descripción completa

Detalles Bibliográficos
Autores principales: Padda, Sukhmani K., Krupitskaya, Yelena, Chhatwani, Laveena, Fisher, George A., Colevas, Alexander D., San Pedro-Salcedo, Melanie, Decker, Rodney, Latz, Jane E., Wakelee, Heather A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313020/
https://www.ncbi.nlm.nih.gov/pubmed/22160298
http://dx.doi.org/10.1007/s00280-011-1792-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313020/
https://www.ncbi.nlm.nih.gov/pubmed/22160298
http://dx.doi.org/10.1007/s00280-011-1792-8

Ejemplares similares